Medivir extends research collaboration with Jiangsu Hengrui

New York, Nov. 21 - Medivir said it and Jiangsu Hengrui Medicine Co. have agreed to extend their research collaboration for developing protease inhibitors against chronic obstructive pulmonary disease.

The companies will now carry out efficacy studies in preclinical test models using compounds developed as part of the collaboration.

If the test data is positive, the project will then move to a preclinical lead optimization phase with the aim of selecting one or more candidate drugs.

Under the agreement, any pharmaceuticals that result from the partnership will be commercialized in China by Jiangsu Hengrui and in the rest of the world by Medivir.

Medivir, based in Huddinge, Sweden, and Jiangsu Hengrui, based in Shanghai, China, began the collaboration in December 2003. They are drawing on Medivir's protease inhibitor program, screening systems and enabling technologies and Jiangsu Hengrui's expertise in medicinal chemistry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.